AINDEX
Markets

Fortress Biotech, Inc. (FBIOP)

FBIOPNASDAQ-CMBiotechnology: Pharmaceutical Preparations

$13.95

+0.2250 (+1.64%) today

Closed, Nov 18, 4:00 PM ET

+1.64% 1D
Market cap
$463.96m
P/E
–
EPS, last 4 quarters
–
Dividend yield
–
Day range
–
52-week range
$6.50 to $21.43
Average volume
–
Previous close
$13.73

Financials

QuarterDec 2025Mar 2026Jun 2026Sep 2026
Revenue$16.08m$16.04m$18.72m$19.16m
Gross profit$10.64m$9.82m$12.57m$13.27m
Operating income-$4.79m-$7.74m-$10.01m-$7.19m
Net income-$3.94m$110.37m-$468.0k-$5.84m

Last four quarters: revenue $69.99m, margin 143.1%, free cash flow –

News

2 latest

The company

Fortress Biotech, Inc. ('Fortress') is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress' portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress' model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company's portfolio of product opportunities.

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ-CM
Region
North America

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.